BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -3.58 | Insider Own | 29.01% | Shs Outstand | 195.86M | Perf Week | -8.05% |
| Market Cap | 13.05B | Forward P/E | - | EPS next Y | 0.08 | Insider Trans | -1.12% | Shs Float | 169.19M | Perf Month | -20.66% |
| Enterprise Value | 14.82B | PEG | - | EPS next Q | -0.67 | Inst Own | - | Short Float | 12.91% | Perf Quarter | 0.51% |
| Income | -696.00M | P/S | 18.85 | EPS this Y | 22.27% | Inst Trans | - | Short Ratio | 7.01 | Perf Half Y | -4.94% |
| Sales | 692.00M | P/B | - | EPS next Y | 103.05% | ROA | -57.20% | Short Interest | 21.85M | Perf YTD | -12.92% |
| Book/sh | -12.79 | P/C | 18.12 | EPS next 5Y | - | ROE | 31.67% | 52W High | 93.42 -28.70% | Perf Year | 30.15% |
| Cash/sh | 3.68 | P/FCF | - | EPS past 3/5Y | - | ROIC | -61.77% | 52W Low | 48.78 36.55% | Perf 3Y | 135.37% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 86.01% 128.84% | Gross Margin | 93.14% | Volatility | 3.94% 3.08% | Perf 5Y | 32.29% |
| Dividend TTM | - | EV/Sales | 21.41 | EPS Y/Y TTM | -24.31% | Oper. Margin | -78.56% | ATR (14) | 2.61 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.17 | Sales Y/Y TTM | 211.71% | Profit Margin | -100.64% | RSI (14) | 20.03 | Recom | 2.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.23 | EPS Q/Q | 17.89% | SMA20 | -10.97% | Beta | 0.95 | Target Price | 110.09 |
| Payout | 0.00% | Debt/Eq | 4.56 | Sales Q/Q | 100.00% | SMA50 | -16.24% | Rel Volume | 1.32 | Prev Close | 67.31 |
| Employees | 999 | LT Debt/Eq | -1.31 | Earnings | Oct 28 | SMA200 | -9.90% | Avg Volume | 3.10M | Price | 66.61 |
| IPO Date | Jun 27, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -35.52% 10.31% | Net Debt/EBITDA | -3.01 | Volume | 4,102,659 | Change | -1.04% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-01-26 | Reiterated | Mizuho | Outperform | $96 → $110 |
| Aug-12-26 | Reiterated | Canaccord Genuity | Buy | $104 → $106 |
| Aug-12-26 | Reiterated | Truist Securities | Buy | $102 → $107 |
| Aug-11-26 | Reiterated | Cantor Fitzgerald | Overweight | $110 |
| Aug-11-26 | Reiterated | Morgan Stanley | Overweight | $98 → $97 |
| Aug-11-26 | Reiterated | Wells Fargo | Overweight | $88 → $102 |
| Aug-11-26 | Reiterated | Piper Sandler | Overweight | $98 → $115 |
| Jul-13-26 | Reiterated | HC Wainwright & Co. | Buy | $110 → $120 |
| Jun-16-26 | Reiterated | Mizuho | Outperform | $53 → $96 |
| Jun-03-26 | Initiated | Canaccord | Buy | $104 |
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 692 | 502 | 222 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 47 | 28 | 4 | — | — | — | — | — | — | |
| Gross Profit | 644 | 474 | 218 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 670 | 555 | 289 | — | — | — | — | — | — | |
| Research and Development | 531 | 478 | 506 | — | — | — | — | — | — | |
| Other Operating Expense | -14 | 10 | 16 | — | — | — | — | — | — | |
| Operating Income | -543 | -569 | -593 | — | — | — | — | — | — | |
| Interest Expense | 90 | 53 | 99 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -74 | -113 | 150 | — | — | — | — | — | — | |
| Net Income Before Taxes | -706 | -735 | -542 | — | — | — | — | — | — | |
| Income Taxes | -2 | 1 | 1 | — | — | — | — | — | — | |
| Consolidated Net Income | -696 | -729 | -536 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -705 | -736 | -543 | — | — | — | — | — | — | |
| Net Income | -696 | -729 | -536 | — | — | — | — | — | — | |
| EPS (Recurring) | -3.58 | -3.79 | -2.88 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.58 | -3.79 | -2.88 | — | — | — | — | — | — | |
| EPS (Diluted) | -3.58 | -3.79 | -2.88 | — | — | — | — | — | — | |
| EBITDA | -603 | -673 | -437 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 18.87 | 30.02 | 22.99 | — | — | — | — | — | — | |
| Gross Margin | 93.06 | 94.42 | 98.20 | — | — | — | — | — | — | |
| Operating Margin | -78.47 | -113.35 | -267.12 | — | — | — | — | — | — | |
| Net Margin | -100.58 | -145.22 | -241.44 | — | — | — | — | — | — | |
| Shares Outstanding | 196 | 197 | 186 | — | — | — | — | — | — | |
| Market Capitalization | 13,056 | 15,069 | 5,104 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer | Aug 19 '26 | Sale | 84.03 | 10,000 | 840,257 | 505,686 | Aug 20 |
| Kumar Neil | Chief Executive Officer | Aug 18 '26 | Sale | 82.53 | 34,980 | 2,886,994 | 243,327 | Aug 20 |
| Kumar Neil | Chief Executive Officer | Aug 16 '26 | Option Exercise | 0.00 | 71,217 | 0 | 314,544 | Aug 18 |
| Apuli Maricel | Chief Accounting Officer | Jul 30 '26 | Sale | 80.06 | 2,000 | 160,120 | 127,401 | Aug 03 |
| Ellis Andrea | Director | Jul 09 '26 | Option Exercise | 16.75 | 17,167 | 287,547 | 39,746 | Jul 13 |
| Ellis Andrea | Director | Jul 09 '26 | Sale | 84.00 | 17,167 | 1,442,028 | 22,579 | Jul 13 |
| Cook Jennifer E. | Director | Jul 09 '26 | Option Exercise | 24.96 | 148,589 | 3,708,335 | 156,972 | Jul 13 |
| Cook Jennifer E. | Director | Jul 09 '26 | Sale | 88.54 | 148,589 | 13,156,008 | 8,383 | Jul 13 |
| Cook Jennifer E. | Director | Jun 24 '26 | Option Exercise | 12.28 | 37,167 | 456,547 | 45,550 | Jun 24 |
| Cook Jennifer E. | Director | Jun 24 '26 | Sale | 70.00 | 37,167 | 2,601,690 | 8,383 | Jun 24 |
| Valantine Hannah | Director | Jun 23 '26 | Sale | 68.57 | 2,196 | 150,580 | 9,259 | Jun 24 |
| Cook Jennifer E. | Director | Jun 23 '26 | Sale | 68.57 | 2,196 | 150,580 | 8,383 | Jun 24 |
| Valantine Hannah | Director | Jun 22 '26 | Option Exercise | 41.73 | 2,808 | 117,178 | 14,263 | Jun 24 |
| Valantine Hannah | Director | Jun 22 '26 | Sale | 68.00 | 2,808 | 190,944 | 11,455 | Jun 24 |
| Cook Jennifer E. | Director | Jun 15 '26 | Sale | 66.62 | 90,240 | 6,012,157 | 6,589 | Jun 17 |